VK2735: Side Effects

Safety Overview#

VK2735's safety profile has been characterized in Phase 2 trials (VENTURE and VENTURE-Oral) enrolling a combined total of approximately 350 patients. As a dual GLP-1/GIP receptor agonist, VK2735's adverse event profile is generally consistent with the GLP-1 agonist class, with gastrointestinal events being the most common. Viking Therapeutics reported that 95% of treatment-emergent adverse events were GI-related, and the majority were mild to moderate.

Gastrointestinal Adverse Events#

GI events were the predominant adverse events in VK2735 clinical trials:

• Overall: 95% of treatment-emergent adverse events were GI-related
• Nausea: Most frequently reported adverse event
• Vomiting, diarrhea, constipation: Common but generally mild to moderate
• Timing: Most common during dose escalation phase
• Resolution: Tended to improve with continued treatment at maintenance dose

Comparison with Other GLP-1/GIP Agonists#

The GI adverse event profile of VK2735 appears broadly consistent with the dual GLP-1/GIP agonist class. Tirzepatide Phase 3 trials reported GI events in approximately 40-50% of patients. Detailed comparative rates for VK2735 have not been disclosed, but the overall tolerability was considered favorable by the investigators.

Treatment Discontinuation#

Discontinuation rates due to adverse events in the VENTURE Phase 2 trial were low, comparable to other GLP-1 agonist therapies. Viking Therapeutics characterized the overall safety profile as favorable.

GLP-1 Agonist Class Warnings#

As a dual GLP-1/GIP receptor agonist, VK2735 is expected to carry the standard GLP-1 class warnings:

Thyroid C-Cell Tumors#

GLP-1 receptor agonists as a class carry warnings about thyroid C-cell tumors based on rodent studies. VK2735 would be expected to carry similar warnings and contraindications for MTC/MEN2.

Pancreatitis#

GLP-1 agonists have been associated with pancreatitis. Patients should report persistent severe abdominal pain.

Gallbladder Disease#

Significant weight loss from any cause increases the risk of cholelithiasis and cholecystitis.

Acute Kidney Injury#

Dehydration from GI adverse events may contribute to acute kidney injury risk.

Formulation-Specific Considerations#

Subcutaneous Formulation#

• Injection site reactions (mild, consistent with other SC therapies)
• Standard injection site rotation recommended

Oral Formulation#

• GI adverse events were also reported with the oral formulation
• No injection site reactions (oral route)
• Specific food interaction data not fully disclosed

Heart Rate Effects#

GLP-1 agonists typically increase resting heart rate by 2-4 bpm. Heart rate effects specific to VK2735 have not been separately characterized in published data.

Special Populations#

Full data on VK2735 safety in renal impairment, hepatic impairment, elderly, and pediatric populations are not yet available. These will be characterized in Phase 3 trials and potential prescribing information.

Drug Interactions#

• Insulin and sulfonylureas: Dose reduction may be needed due to hypoglycemia risk
• Oral medications: GLP-1 receptor agonism delays gastric emptying, potentially affecting absorption of co-administered drugs
• Oral contraceptives: Consider alternative contraception during initiation due to gastric emptying effects

Safety Profile Context#

VK2735 belongs to the Metabolic category of research peptides. Understanding the side effect profile of VK2735 is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of VK2735. Side effect severity and frequency are based on available clinical data.

Nausea#

Severity: mild | Frequency: very-common

Most common adverse event. As a dual GLP-1/GIP agonist, nausea is expected during dose escalation. Generally mild to moderate and tends to improve with continued treatment.

Vomiting#

Severity: mild | Frequency: common

Common GI adverse event reported in Phase 2 trials. Generally transient and mild to moderate. Dose escalation mitigates severity.

Diarrhea#

Severity: mild | Frequency: common

Commonly reported GI adverse event. Usually mild to moderate and self-limiting.

Constipation#

Severity: mild | Frequency: common

Related to slowed GI transit from GLP-1 receptor activation and potentially GIP-mediated effects.

Injection site reactions#

Severity: mild | Frequency: common

Reported with the subcutaneous formulation. Generally mild and consistent with other injectable peptide therapies.

Contraindications#

The following contraindications have been identified for VK2735 based on available research and pharmacological considerations:

• VK2735 is investigational and not approved for any indication. Use only within clinical trials.
• Expected GLP-1 agonist class contraindication: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy (GLP-1 agonist class)
• Prior serious hypersensitivity to VK2735 or excipients

Individuals with any of these conditions should not use VK2735 without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for VK2735:

• Insulin and sulfonylureas: Increased risk of hypoglycemia when combined (GLP-1 agonist class interaction)
• Oral medications: GLP-1 receptor agonists may delay gastric emptying and affect absorption of co-administered oral drugs
• Oral contraceptives: Gastric emptying delay may reduce absorption; consider non-oral contraception during initiation

Drug interaction studies for VK2735 remain limited. Researchers should exercise caution when combining VK2735 with other compounds and consult relevant pharmacological references.

Related Reading#

• VK2735 overview and research guide
• VK2735 dosing protocols
• VK2735 risks and legal status